Published On : November 2017 Pages : 150 Category: Pharmaceuticals Report Code : HC11338
Industry Outlook and Trend Analysis
The Protein Therapeutics Market was worth USD billion in the year of 2017 and is expected to reach approximately USD billion by 2022, while registering itself at a compound annual growth rate (CAGR) of % during the forecast period. Therapeutic proteins are a critical class of pharmaceuticals, which are managed to treat a variety of various diseases, for example, infectious diseases, cancer, and others. These medications hold critical potential to enhance human health. The requirement for protein therapeutics has expanded impressively, attributable to increment in predominance of chronic diseases and advancement of plasma-determined treatments. Moreover, increasing awareness for protein therapeutics among people supports the market development. Nonetheless, high expenses related with remedial proteins and stringent government directions towards protein therapeutics limit market development. On the other hand, implementation of protein therapeutics for novel signs and undiscovered capability of emerging nations are expected to give lucrative chances to the market players.
On the basis of product the Protein Therapeutics Market is segmented into Insulin, Erythropoietin, Human Growth Hormone, Monoclonal Antibodies, Fusion Protein, Interferon and Follicle Stimulating Hormone. Insulin is a hormone that assists in controlling (glucose) levels in the blood, which tend to rise after meals. Individuals experiencing type-2 diabetes are impervious to the glucose-lowering impacts of insulin. Monoclonal immunizer treatment is a type of immunotherapy that makes use of monoclonal antibodies (mAb) to bind monospecifically to specific cells or proteins. The goal is that this treatment will stimulate the immune system of the patient to target those cells. Erythropoietin (Epo) is the primary growth regulator of red blood cells, and recombinant human erythropoietin (rHuEpo) is consequently useful in treating anemia, fundamentally in cancer and kidney disease. rHuEpo treatment was observed to be related with delayed survival of various myeloma (MM) patients. HGH or the Human Growth Hormone is an anabolic, proteinaceous hormone, which is emitted by the Pituitary gland of the endocrinal framework. Some recent clinical examinations have substantiated the urgent and crucial part that HGH plays, in turning around the impacts of maturing, enhancing physical and psychological health.
Application Outlook and Trend Analysis
On the basis of application the Protein Therapeutics Market is segmented into Immunologic Disorders, Cancer, Genetic Disorders, Metabolic Disorders, Hematological Disorders and Hormonal Disorders. Therapeutic protein drugs are an imperative class of prescriptions serving patients most needing novel treatments. Protein therapeutics has been produced to treat a wide range of clinical issues such as genetic disorders, cancer, exposure to infectious agents and inflammation. Therapeutic proteins allow an individualized treatment approach by supporting a particularly focused on restorative process by repaying the inadequacy of a fundamental protein. The quickest developing class of therapeutic proteins is antibodies. From one viewpoint they bolster the immune response and then again they can instigate the collection of therapeutic agents at a tumor site through conjugation/combination. Antibodies are not just a helpful instrument in the treatment of cancer yet additionally in the treatment of auto-immune disease.
Regional Outlook and Trend Analysis
In terms of geography, the worldwide protein therapeutics market has been segmented into North America, Latin America, Europe, Middle East, and Africa. These regions are additionally portioned and broke down as per the key nations contributing essentially to the advancement of the protein therapeutics advertise over these areas. Factors, for example, administrative structure of these locales encompassing the field of protein therapeutics, the procedure of endorsement protein therapeutics items, and the general development prospects of the market.
Competitive Insights
The major players in the Protein Therapeutics Market are Roche Holding AG, Pfizer, Johnson & Johnson, Baxter International, Abbott Laboratories, Eli Lilly and Company and Novo Nordisk. The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
The global Protein Therapeutics Market is segmented as follows-
By Product:
By Application:
By Region
Some of the key questions answered by the report are:
Market Classification
Table of Contents
1. Introduction
1.1. Report Description
1.2. Research Methodology
1.2.1. Secondary Research
1.2.2. Primary Research
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.1.1. Increase in R&D Investments
3.2.1.2. Rise in Incidence of Chronic Diseases
3.2.1.3. Rise in Healthcare Expenditure
3.2.1.4. Growth in Proteomics Research
3.2.2. Restraints
3.2.2.1. High Production Costs
3.2.3. Opportunities
3.2.3.1. Greater Potency With Reduced Costs and Increasing Affordability
4. Protein Therapeutics Market, By Product
4.1. Introduction
4.2. Protein Therapeutics Market Assessment and Forecast, By Product, 2012-2022
4.3. Monoclonal Antibodies
4.3.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
4.4. Insulin
4.4.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
4.5. Fusion Protein
4.5.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
4.6. Erythropoietin
4.6.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
4.7. Interferon
4.7.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
4.8. Human Growth Hormone
4.8.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
4.9. Follicle Stimulating Hormone
4.9.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
5. Protein Therapeutics Market, By Application
5.1. Introduction
5.2. The Protein Therapeutics Market Assessment and Forecast, By Application, 2012-2022
5.3. Metabolic Disorders
5.3.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
5.4. Immunologic Disorders
5.4.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
5.5. Hematological Disorders
5.5.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
5.6. Cancer
5.6.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
5.7. Hormonal Disorders
5.7.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
5.8. Genetic Disorders
5.8.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
5.9. Other Applications
5.9.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
6. Protein Therapeutics Market, By Region
6.1. Introduction
6.2. Protein Therapeutics Market Assessment and Forecast, By Region, 2012-2022 ($Million)
6.3. North America
6.3.1. Market Assessment and Forecast, By Country, 2012-2022 ($Million)
6.3.2. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
6.3.3. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
6.3.4. U.S.
6.3.4.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
6.3.4.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
6.3.5. Canada
6.3.5.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
6.3.5.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
6.3.6. Mexico
6.3.6.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
6.3.6.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
6.4. Europe
6.4.1. Market Assessment and Forecast, By Country, 2012-2022 ($Million)
6.4.2. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
6.4.3. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
6.4.4. Germany
6.4.4.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
6.4.4.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
6.4.5. France
6.4.5.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
6.4.5.2. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
6.4.6. UK
6.4.6.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
6.4.6.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
6.4.7. Italy
6.4.7.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
6.4.7.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
6.4.8. Spain
6.4.8.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
6.4.8.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
6.4.9. Rest of Europe
6.4.9.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
6.4.9.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
6.5. Asia-Pacific
6.5.1. Market Assessment and Forecast, By Country, 2012-2022 ($Million)
6.5.2. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
6.5.3. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
6.5.4. Japan
6.5.4.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
6.5.4.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
6.5.5. China
6.5.5.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
6.5.5.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
6.5.6. Australia
6.5.6.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
6.5.6.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
6.5.7. India
6.5.7.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
6.5.7.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
6.5.8. South Korea
6.5.8.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
6.5.8.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
6.5.9. Rest of Asia-Pacific
6.5.9.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
6.5.9.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
6.6. Rest of the World
6.6.1. Market Assessment and Forecast, By Country, 2012-2022 ($Million)
6.6.2. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
6.6.3. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
6.6.4. Brazil
6.6.4.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
6.6.4.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
6.6.5. Turkey
6.6.5.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
6.6.5.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
6.6.6. Saudi Arabia
6.6.6.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
6.6.6.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
6.6.7. South Africa
6.6.7.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
6.6.7.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
6.6.8. United Arab Emirates
6.6.8.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
6.6.8.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
6.6.9. Others
6.6.9.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
6.6.9.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
7. Company Profiles
7.1. ABBOTT LABORATORIES
7.1.1. Business Overview
7.1.2. Product Portfolio
7.1.3. Key Financials
7.1.4. Strategic Developments
7.2. AMGEN, INC.
7.2.1. Business Overview
7.2.2. Product Portfolio
7.2.3. Key Financials
7.2.4. Strategic Developments
7.3. BAXTER INTERNATIONAL INC.
7.3.1. Business Overview
7.3.2. Product Portfolio
7.3.3. Key Financials
7.3.4. Strategic Developments
7.4. ELI LILLY AND COMPANY
7.4.1. Business Overview
7.4.2. Product Portfolio
7.4.3. Key Financials
7.4.4. Strategic Developments
7.5. F. HOFFMANN-LA ROCHE AG
7.5.1. Business Overview
7.5.2. Product Portfolio
7.5.3. Strategic Developments
7.6. JOHNSON & JOHNSON
7.6.1. Business Overview
7.6.2. Product Portfolio
7.6.3. Strategic Developments
7.7. MERCK & CO., INC.
7.7.1. Business Overview
7.7.2. Product Portfolio
7.7.3. Key Financials
7.7.4. Strategic Developments
7.8. NOVO NORDISK A/S
7.8.1. Business Overview
7.8.2. Product Portfolio
7.8.3. Strategic Developments
7.9. PFIZER INC.
7.9.1. Business Overview
7.9.2. Product Portfolio
7.9.3. Strategic Developments
7.10. SANOFI
7.10.1. Business Overview
7.10.2. Product Portfolio
7.10.3. Key Financials
7.10.4. Strategic Developments
List of Tables
List of Tables
Table 1.Global Protein Therapeutics Market, By Product ($Million), 2012-2022
Table 2.Monoclonal Antibodies Market, By Region ($Million), 2012-2022
Table 3.Insulin Market, By Region ($Million), 2012-2022
Table 4.Fusion Protein Market, By Region ($Million), 2012-2022
Table 4.Erythropoietin Market, By Region ($Million), 2012-2022
Table 4.Interferon Market, By Region ($Million), 2012-2022
Table 5.Human Growth Hormone Market, By Region ($Million), 2012-2022
Table 6.Follicle Stimulating Hormone Market, By Region ($Million), 2012-2022
Table 6.Global Protein Therapeutics Market, By Application ($Million), 2012-2022
Table 7.Metabolic Disorders Market, By Region ($Million), 2012-2022
Table 8.Immunologic Disorders Market, By Region ($Million), 2012-2022
Table 9.Hematological Disorders Market, By Region ($Million), 2012-2022
Table 10.Cancer Market, By Type ($Million), 2012-2022
Table 11.Hormonal Disorders Market, By Region ($Million), 2012-2022
Table 12.Genetic Disorders Market, By Region ($Million), 2012-2022
Table 13.Other Applications Market, By Region ($Million), 2012-2022
Table 14.North America Protein Therapeutics Market, By Country, 2012-2022 ($Million)
Table 15.North America Protein Therapeutics Market, By Product, 2012-2022 ($Million)
Table 16.North America Protein Therapeutics Market, By Application, 2012-2022 ($Million)
Table 17.U.S. Protein Therapeutics Market, by Product, 2012-2022 ($Million)
Table 18.U.S. Protein Therapeutics Market, by Application, 2012-2022 ($Million)
Table 19.Canada Protein Therapeutics Market, By Product, 2012-2022 ($Million)
Table 20.Canada Protein Therapeutics Market, By Application, 2012-2022 ($Million)
Table 21.Mexico Protein Therapeutics Market, By Product, 2012-2022 ($Million)
Table 22.Mexico Protein Therapeutics Market, By Application, 2012-2022 ($Million)
Table 23.Europe Protein Therapeutics Market, By Country, 2012-2022 ($Million)
Table 24.Europe Protein Therapeutics Market, By Product, 2012-2022 ($Million)
Table 25.Europe Protein Therapeutics Market, By Application, 2012-2022 ($Million)
Table 26.Germany Protein Therapeutics Market, By Product, 2012-2022 ($Million)
Table 27.Germany Protein Therapeutics Market, By Application, 2012-2022 ($Million)
Table 28.France Protein Therapeutics Market, By Product, 2012-2022 ($Million)
Table 29.France Protein Therapeutics Market, By Application, 2012-2022 ($Million)
Table 30.UK Protein Therapeutics Market, By Product, 2012-2022 ($Million)
Table 31.UK Protein Therapeutics Market, By Application, 2012-2022 ($Million)
Table 32.Italy Protein Therapeutics Market, By Product, 2012-2022 ($Million)
Table 33.Italy Protein Therapeutics Market, By Application, 2012-2022 ($Million)
Table 34.Spain Protein Therapeutics Market, By Product, 2012-2022 ($Million)
Table 35.Spain Protein Therapeutics Market, By Application, 2012-2022 ($Million)
Table 36.Rest of Europe Protein Therapeutics Market, By Product, 2012-2022 ($Million)
Table 37.Rest of Europe Protein Therapeutics Market, By Application, 2012-2022 ($Million)
Table 38.Asia-Pacific Protein Therapeutics Market, By Country, 2012-2022 ($Million)
Table 39.Asia-Pacific Protein Therapeutics Market, By Product, 2012-2022 ($Million)
Table 40.Asia-Pacific Protein Therapeutics Market, By Application, 2012-2022 ($Million)
Table 41.Japan Protein Therapeutics Market, By Product, 2012-2022 ($Million)
Table 42.Japan Protein Therapeutics Market, By Application, 2012-2022 ($Million)
Table 43.China Protein Therapeutics Market, By Product, 2012-2022 ($Million)
Table 44.China Protein Therapeutics Market, By Application, 2012-2022 ($Million)
Table 45.Australia Protein Therapeutics Market, By Product, 2012-2022 ($Million)
Table 46.Australia Protein Therapeutics Market, By Application, 2012-2022 ($Million)
Table 47.India Protein Therapeutics Market, By Product, 2012-2022 ($Million)
Table 48.India Protein Therapeutics Market, By Application, 2012-2022 ($Million)
Table 49.South Korea Protein Therapeutics Market, By Product, 2012-2022 ($Million)
Table 50.South Korea Protein Therapeutics Market, By Application, 2012-2022 ($Million)
Table 51.Rest of Asia-Pacific Protein Therapeutics Market, By Product, 2012-2022 ($Million)
Table 52.Rest of Asia-Pacific Protein Therapeutics Market, By Application, 2012-2022 ($Million)
Table 53.Rest of the World Protein Therapeutics Market, By Country, 2012-2022 ($Million)
Table 54.Rest of the World Protein Therapeutics Market, By Product, 2012-2022 ($Million)
Table 55.Rest of the World Protein Therapeutics Market, By Application, 2012-2022 ($Million)
Table 56.Brazil Protein Therapeutics Market, By Product, 2012-2022 ($Million)
Table 57.Brazil Protein Therapeutics Market, By Application, 2012-2022 ($Million)
Table 58.Turkey Protein Therapeutics Market, By Product, 2012-2022 ($Million)
Table 59.Turkey Protein Therapeutics Market, By Application, 2012-2022 ($Million)
Table 60.Saudi Arabia Protein Therapeutics Market, By Product, 2012-2022 ($Million)
Table 61.Saudi Arabia Protein Therapeutics Market, By Application, 2012-2022 ($Million)
Table 62.South Africa Protein Therapeutics Market, By Product, 2012-2022 ($Million)
Table 63.South Africa Protein Therapeutics Market, By Application, 2012-2022 ($Million)
Table 64.United Arab Emirates Protein Therapeutics Market, By Product, 2012-2022 ($Million)
Table 65.United Arab Emirates Protein Therapeutics Market, By Application, 2012-2022 ($Million)
Table 66.Others Protein Therapeutics Market, By Product, 2012-2022 ($Million)
Table 67.Others Protein Therapeutics Market, By Application, 2012-2022 ($Million)
Table 68.ABBOTT LABORATORIES: Key Strategic Developments, 2017-2017
Table 69.AMGEN, INC.: Key Strategic Developments, 2017-2017
Table 70.BAXTER INTERNATIONAL INC.: Key Strategic Developments, 2017-2017
Table 71.ELI LILLY AND COMPANY: Key Strategic Developments, 2017-2017
Table 72.F. HOFFMANN-LA ROCHE AG: Key Strategic Developments, 2017-2017
Table 73.JOHNSON & JOHNSON: Key Strategic Developments, 2017-2017
Table 74.MERCK & CO. INC.: Key Strategic Developments, 2017-2017
Table 75.NOVO NORDISK A/S: Key Strategic Developments, 2017-2017
Table 76.PFIZER INC.: Key Strategic Developments, 2017-2017
Table 77.SANOFI: Key Strategic Developments, 2017-2017
List of Figures
List of Figures
Figure 1.Global Protein Therapeutics Market Share, By Product, 2012 & 2022
Figure 2.Protein Therapeutics Market, By Application, 2012 & 2022, ($Million)
Figure 3.Protein Therapeutics Market, By Region, 2012 & 2022, ($Million)
Figure 4.ABBOTT LABORATORIES: Net Revenues, 2017-2017 ($Million)
Figure 5.ABBOTT LABORATORIES: Net Revenue Share, By Segment, 2017
Figure 6.ABBOTT LABORATORIES: Net Revenue Share, By Geography, 2017
Figure 7.AMGEN, INC.: Net Revenues, 2017-2017 ($Million)
Figure 8.AMGEN, INC.: Net Revenue Share, By Segment, 2017
Figure 9.AMGEN, INC.: Net Revenue Share, By Geography, 2017
Figure 10.BAXTER INTERNATIONAL INC.: Net Revenues, 2017-2017 ($Million)
Figure 11.BAXTER INTERNATIONAL INC.: Net Revenue Share, By Segment, 2017
Figure 12.BAXTER INTERNATIONAL INC.: Net Revenue Share, By Geography, 2017
Figure 13.ELI LILLY AND COMPANY: Net Revenues, 2017-2017 ($Million)
Figure 14.ELI LILLY AND COMPANY: Net Revenue Share, By Segment, 2017
Figure 15.ELI LILLY AND COMPANY: Net Revenue Share, By Geography, 2017
Figure 16.SANOFI: Net Revenues, 2017-2017 ($Million)
Figure 17.SANOFI: Net Revenue Share, By Segment, 2017
Figure 18.SANOFI: Net Revenue Share, By Geography, 2017
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
Data Collection Matrix |
Supply Side |
Demand Side |
Primary Data Sources |
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
Qualitative Data |
Quantitative Data (2017-2025) |
|
|